Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Suven Pharmaceuticals Ltd - 543064 - Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31St December, 2022

 With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. February 6, 2023, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and nine months ended 31st December, 2022. We are enclosing herewith the following documents: 1) Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 2) Limited Review Reports on the financial results as mentioned above and 3) Earnings Presentation of our company to investors We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:55 P.M. This is for your information and record.
06-02-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Tuesday, February 7, 2023 at 12:00 Noon IST to discuss the Un-Audited Financial Results for the Q3 & 9M FY23, to be declared on February 6, 2023. This is for your information and record.
31-01-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Monday, The February 6, 2023

 Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2023 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the February 6, 2023 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No. 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): To consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the third quarter and nine months ended December 31, 2022 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st January, 2023 as per PIT Code of the Company. Trading window will be opened from 10th February, 2023. You are requested to take this notice on your record.
30-01-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in terms of SEBI Circular No. SEBIIHO/MIRSD/MIRSD_RTAMB/P/CIR /2022/8 dated January 25, 2022, this is to inform you that the Company has received intimation from our RTA dated January 27, 2023 regarding issued a 'Letter of Confirmation' in lieu of share certificate(s) reported as lost/misplaced by the following shareholders(s).
29-01-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to intimate you that the CRISIL has assigned the following ratings to the Bank facilities of our Company as per communication received on January 16, 2023. Facilities Rating Long-term Bank Facilities CRISIL A+/Watch Developing (Placed on 'Rating Watch with Developing Implications') Short-term Bank Facilities CRISIL A1+/Watch Developing (Placed on 'Rating Watch with Developing Implications') This is for your information and record.
16-01-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Draft Letter of Offer

 Kotak Mahindra Capital Company Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the public shareholders of Suven Pharmaceuticals Ltd ("Target Company").
09-01-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, please find enclosed herewith the Confirmation Certificates issued by KFin Technologies Limited, Registrar and Share Transfer Agents of the Company, for the quarter ended December 31, 2022. This is for your information and record.
06-01-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Detailed Public Statement

 Kotak Mahindra Capital Company Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Detailed Public Statement in terms of Regulation 3(1), Regulation 4 read with Regulation 13(4), Regulation 14(3), Regulation 15(2) and other applicable Regulations of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations , 2011, as amended, to the public shareholders of Suven Pharmaceuticals Ltd ("Target Company").
02-01-2023
Bigul

Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st January, 2023 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter/nine months ending 31st December, 2022, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and record.
30-12-2022
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the conference call for the investors held on December 26, 2022. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-events This is for your information and record.
30-12-2022
Next Page
Close

Let's Open Free Demat Account